Trials / Completed
CompletedNCT01056679
Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients
Phase I Trial of AVD Plus Lenalidomide (Revlimid) in Elderly Intermediate or Advanced Stage Hodgkin Lymphoma Patients
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- University of Cologne · Academic / Other
- Sex
- All
- Age
- 60 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine within the scope of the trial what the maximum tolerated dose (MTD) of lenalidomide in combination with AVD should be.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Doxorubicine | 50mg/m2 day 1 + 15 |
| DRUG | DTIC | 375mg/m2 day 1 + 15 |
| DRUG | Lenalidomide | day 1 - 21 |
| DRUG | Vinblastine | 6mg/m2 day 1 + 15 |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2014-04-01
- Completion
- 2016-02-01
- First posted
- 2010-01-26
- Last updated
- 2018-03-22
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01056679. Inclusion in this directory is not an endorsement.